HomeCompareOCEAW vs NOBL

OCEAW vs NOBL: Dividend Comparison 2026

OCEAW yields 6711.41% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEAW wins by $1097629163471472.38M in total portfolio value
10 years
OCEAW
OCEAW
● Live price
6711.41%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1097629163471472.38M
Annual income
$1,066,373,173,675,476,400,000.00
Full OCEAW calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — OCEAW vs NOBL

📍 OCEAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCEAWNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEAW + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEAW pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEAW
Annual income on $10K today (after 15% tax)
$570,469.80/yr
After 10yr DRIP, annual income (after tax)
$906,417,197,624,154,900,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, OCEAW beats the other by $906,417,197,624,154,900,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEAW + NOBL for your $10,000?

OCEAW: 50%NOBL: 50%
100% NOBL50/50100% OCEAW
Portfolio after 10yr
$548814581735736.19M
Annual income
$533,186,586,837,738,200,000.00/yr
Blended yield
97.15%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEAW buys
0
NOBL buys
0
No recent congressional trades found for OCEAW or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCEAWNOBL
Forward yield6711.41%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1097629163471472.38M$22.8K
Annual income after 10y$1,066,373,173,675,476,400,000.00$246.19
Total dividends collected$1095532211199846.75M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: OCEAW vs NOBL ($10,000, DRIP)

YearOCEAW PortfolioOCEAW Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$681,841$671,140.94$10,914$214.34+$670.9KOCEAW
2$43,496,987$42,767,417.65$11,897$218.63+$43.49MOCEAW
3$2,596,337,307$2,549,795,530.67$12,952$222.72+$2596.32MOCEAW
4$145,018,660,220$142,240,579,301.68$14,086$226.62+$145018.65MOCEAW
5$7,580,273,425,477$7,425,103,459,041.20$15,302$230.33+$7580273.41MOCEAW
6$370,837,750,892,272$362,726,858,327,011.50$16,607$233.85+$370837750.88MOCEAW
7$16,981,014,621,956,098$16,584,218,228,501,366.00$18,007$237.18+$16981014621.94MOCEAW
8$727,896,026,099,293,400$709,726,340,453,800,300.00$19,508$240.35+$727896026099.27MOCEAW
9$29,211,205,416,818,827,000$28,432,356,668,892,580,000.00$21,116$243.35+$29211205416818.81MOCEAW
10$1,097,629,163,471,472,400,000$1,066,373,173,675,476,400,000.00$22,841$246.19+$1097629163471472.38MOCEAW

OCEAW vs NOBL: Complete Analysis 2026

OCEAWStock

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Full OCEAW Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this OCEAW vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEAW vs SCHDOCEAW vs JEPIOCEAW vs OOCEAW vs KOOCEAW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.